Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anesiva’s Adlea gears up for Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Anesiva will conduct two Phase III trials - one in knee replacement and one in bunionectomy surgeries - for its post-surgical pain candidate Adlea, the firm announces Oct. 10. A long-acting, non-opiate analgesic, Adlea is designed to provide pain relief for weeks to months following a single application. Both trials are expected to begin in the first half of 2008. Anesiva CEO John McLaughlin said the firm is also examining Adlea for other indications such as tendonitis and nerve damage...

Related Content

R&D In Brief





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts